Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahea…
. - Fresenius achieves the raised outlook for FY/23. Strong final quarter with continued good development of the Operati…
This agreement between Thermo Fisher Scientific and Aesku gives customers access to a comprehensive portfolio of autoimm…
Fresenius makes use of the governmental compensation and reimbursement payments of up to €300 million (from the curr…
. - Excellent Group revenue growth of 6% in constant currency to €5.5 billion; driven by Operating Companies and Freseni…
. - Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for h…
. Excellent Group revenue growth of 7% in constant currency to €10.4 billion; Operating Companies with very strong 8%…
Soft tissue sarcomas are a rare group of malignant tumors arising from connective tissue cells, of which more than 70 di…
Fresenius has signed the German "Charta der Vielfalt" (Diversity Charter). The healthcare group is thus taking a strong…